Diabetes comprises a collection of metabolic disorders in which chronic hyperglycaemia arises as a result of insulin deficiency, insulin resistance, or a combination of the two.
Featured Learning Zones
There are three main types of diabetes. The most common, Type 2 diabetes, is often secondary to weight gain and involves impaired insulin secretion and the development of insulin resistance.
Type 1 diabetes is characterised by absolute insulin deficiency resulting from autoimmune destruction of the β-cells of the pancreas.
Gestational diabetes occurs when the pancreas fails to produce sufficient insulin to compensate for the state of increased insulin resistance that occurs during pregnancy.
Symptoms of diabetes include polyuria, thirst, infections and blurred vision, with suspected cases confirmed using blood tests.
Long-term diabetes is associated with various microvascular complications including retinopathy and nephropathy, as well as macrovascular disease, so effective treatment to normalise blood glucose levels is vital. While patients with type 1 diabetes require treatment with insulin, early type 2 diabetes can often be managed through lifestyle modifications, although glucose lowering agents may be required, particularly as the disease progresses.
To find out more about Type 2 diabetes, visit our dedicated Cardiovascular Metabolism Learning Zone which includes further information regarding the epidemiology and management for this condition.
Related news and insights
Biocon Biologics Ltd., a subsidiary of Biocon has announced that Kixelle, a biosimilar Insulin Aspart co-developed with Viatris Inc. (NASDAQ: VTRS), has received marketing authorization approval from the European Commission following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Novo Nordisk has announced the submission of a label expansion application to the FDA for the existing marketing authorisation for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg.
Lexicon Pharmaceuticals announced that it has received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase III clinical studies of Zynquista (sotagliflozin) can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.